IMMX

Company Overview — What Does Immix Biopharma, Inc. Do?

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California. Immix Biopharma, Inc. (IMMX) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Ilya Rachman and employs approximately 9 people. With a market capitalization of $457M, IMMX is one of the notable companies in the Healthcare sector.

Immix Biopharma, Inc. (IMMX) Stock Rating — Hold (April 2026)

As of April 2026, Immix Biopharma, Inc. receives a Hold rating with a composite score of 35.9/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.IMMX ranks #1,374 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Immix Biopharma, Inc. ranks #109 of 838 stocks, placing it in the top quartile of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

IMMX Stock Price and 52-Week Range

Immix Biopharma, Inc. (IMMX) currently trades at $9.44. The stock lost $0.31 (3.2%) in the most recent trading session. The 52-week high for IMMX is $11.61, which means the stock is currently trading -18.7% from its annual peak. The 52-week low is $1.34, putting the stock 604.5% above its annual trough. Recent trading volume was 399K shares, suggesting relatively thin trading activity.

Is IMMX Overvalued or Undervalued? — Valuation Analysis

Immix Biopharma, Inc. (IMMX) carries a value factor score of 26/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 5.14x, versus the sector average of 2.75x.

At current multiples, Immix Biopharma, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Immix Biopharma, Inc. Profitability — ROE, Margins, and Quality Score

Immix Biopharma, Inc. (IMMX) earns a quality factor score of 20/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -27.6%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -24.7% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

IMMX Debt, Balance Sheet, and Financial Health

Immix Biopharma, Inc. has a debt-to-equity ratio of 12.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 10.01x, indicating strong short-term liquidity. Total debt on the balance sheet is $965,053. Cash and equivalents stand at $16M.

IMMX has a beta of 1.43, meaning it is more volatile than the broader market — a $10,000 investment in IMMX would be expected to move 42.7% more than the S&P 500 on any given day. The stability factor score for Immix Biopharma, Inc. is 27/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Immix Biopharma, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Immix Biopharma, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.89. Net income for the quarter was $-26M. Operating income came in at $-26M.

In FY 2025, Immix Biopharma, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.89. Net income for the quarter was $-29M. Operating income came in at $-30M.

In Q3 2025, Immix Biopharma, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.24. Net income for the quarter was $-8M. Operating income came in at $-8M.

In Q2 2025, Immix Biopharma, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.22. Net income for the quarter was $-7M. Operating income came in at $-7M.

Over the past 8 quarters, Immix Biopharma, Inc. has experienced revenue contraction from $0 to $0. Investors analyzing IMMX stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

IMMX Dividend Yield and Income Analysis

Immix Biopharma, Inc. (IMMX) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

IMMX Momentum and Technical Analysis Profile

Immix Biopharma, Inc. (IMMX) has a momentum factor score of 78/100, indicating strong price momentum with the stock outperforming the majority of the market over recent periods. Stocks with high momentum scores have historically tended to continue their outperformance in the near term. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 13/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

IMMX vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Immix Biopharma, Inc. (IMMX) ranks #109 out of 838 stocks based on the Blank Capital composite score. This places IMMX in the top quartile of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing IMMX against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full IMMX vs S&P 500 (SPY) comparison to assess how Immix Biopharma, Inc. stacks up against the broader market across all factor dimensions.

IMMX Next Earnings Date

No upcoming earnings date has been announced for Immix Biopharma, Inc. (IMMX) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy IMMX? — Investment Thesis Summary

Immix Biopharma, Inc. presents a balanced picture with arguments on both sides. The quality score of 20/100 flags below-average profitability. The value score of 26/100 indicates premium valuation. Price momentum is positive at 78/100, suggesting the trend favors buyers. High volatility (stability score 27/100) increases portfolio risk.

In summary, Immix Biopharma, Inc. (IMMX) earns a Hold rating with a composite score of 35.9/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on IMMX stock.

Related Resources for IMMX Investors

Explore more research and tools: IMMX vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare IMMX head-to-head with peers: IMMX vs AZN, IMMX vs SLGL, IMMX vs VMD.